Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung

Trial Details

NCT ID
NCT06096844
Phase
PHASE3
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Carboplatin
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Nab-paclitaxel
  • Paclitaxel
  • Pembrolizumab
Locations (sample)
  • Fayetteville, Arkansas, United States|36.06258,-94.15743
  • Fort Smith, Arkansas, United States|35.38592,-94.39855
  • Rogers, Arkansas, United States|36.33202,-94.11854
  • Springdale, Arkansas, United States|36.18674,-94.12881
  • Dublin, California, United States|37.70215,-121.93579

Key Eligibility Criteria

  • STEP 1 REGISTRATION
  • Patient must be ≥ 70 years of age
  • Patient must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with PD-L1 Tumor Proportion Score (TPS) range of 1-49%
  • Patient must have Stage IIIB, IIIC or IV disease and not be candidates for combined chemo-radiation. NOTE: Prior chemo-radiation therapy (RT) for s…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →